[Serum levels of interleukin-6 and interleukin-10 in patients with multiple sclerosis during intravenous immunoglobulin infusion].
Intravenous immunoglobulin (IVIG) therapy is a recognized treatment of inflammatory and autoimmune disorders and its efficacy in multiple sclerosis (MS) has been proven in a few double-blind studies. IVIG has several effects on the immune system that could have a beneficial influence on disease process in MS and one of these effects are significant changes in serum levels of circulating cytokines after IVIG infusions. As interleukin-6 (IL-6) and interleukin-10 (IL-10) play important role as pro- and anti-inflammatory factors, in vivo modulation of these cytokines may account for immunomodulatory and anti-inflammatory effect of IVIG therapy. In order to better understand mechanism of action of low-dose IVIG cyclic therapy we have investigated serum levels of IL-6 and IL-10 before and a day after IVIG infusion in patients with MS.


METHODS
Serum levels of IL-6 and IL-10 were assayed in 20 patients with MS before and 24 hours after infusion of 2.5 g (n = 9) and 5 g (n = 11) of IVIG.


RESULTS
Significant changes of IL-6 nor IL-10 serum levels after IVIG infusions in both doses of 2.5 g and 5 g were not observed.


CONCLUSIONS
Single infusion of 2.5 g nor 5 g of IVIG does not alter serum levels of neither pro-inflammatory IL-6 nor anti-inflammatory IL-10. As modulating influence of IVIG on the serum levels of IL-6 and IL-10 seems to be dose-dependent, further investigations of these cytokines levels after infusions of higher doses of IVIG might be efficient in the assessment of its usability in monitoring of immune system response to IVIG treatment.
Kazibutowska
Zofia
Z
Z Kliniki Neurologii Katedry Neurologii Slaskiej Akademii Medycznej w Katowicach Górnoślaskie Centrum Medyczne. neurologia@gcm.pl
Motta
Ewa
E
Huć
Maciej
M
Strzała-Orzeł
Michalina
M
Woźnik
Gabriela
G
D000328:Adult; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000097:blood; D016753:Interleukin-10 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy*; D044967:Serum / Q000737:chemistry / Q000276:immunology; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D015850:Interleukin-6; D016753:Interleukin-10